WO2002024633A1 - Derives d'acide phenylpropionique - Google Patents

Derives d'acide phenylpropionique Download PDF

Info

Publication number
WO2002024633A1
WO2002024633A1 PCT/JP2001/008151 JP0108151W WO0224633A1 WO 2002024633 A1 WO2002024633 A1 WO 2002024633A1 JP 0108151 W JP0108151 W JP 0108151W WO 0224633 A1 WO0224633 A1 WO 0224633A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid derivatives
phenylpropionic acid
halogeno
alkoxy
alkyl
Prior art date
Application number
PCT/JP2001/008151
Other languages
English (en)
Japanese (ja)
Inventor
Hiroaki Yanagisawa
Makoto Takamura
Takashi Fujita
Toshihiko Fujiwara
Original Assignee
Sankyo Company, Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Company, Limited filed Critical Sankyo Company, Limited
Priority to AU2001288067A priority Critical patent/AU2001288067A1/en
Publication of WO2002024633A1 publication Critical patent/WO2002024633A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/54—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des dérivés d'acide phénylpropionique de la formule générale (I) ou leurs sels ou esters pharmacologiquement acceptables, qui sont fortement actifs et extrêmement sûrs, et peuvent améliorer l'hyperlipidémie, l'hyperglycémie, etc. Dans ladite formule, X est CH ou N; R1 est H, alkyle C¿1-6?, alcoxy C1-6, ou halogéno; et R?2¿ est alkyle C¿1-6?, alcoxy C1-6, ou halogéno.
PCT/JP2001/008151 2000-09-21 2001-09-19 Derives d'acide phenylpropionique WO2002024633A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001288067A AU2001288067A1 (en) 2000-09-21 2001-09-19 Phenylpropionic acid derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-286495 2000-09-21
JP2000286495 2000-09-21

Publications (1)

Publication Number Publication Date
WO2002024633A1 true WO2002024633A1 (fr) 2002-03-28

Family

ID=18770409

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/008151 WO2002024633A1 (fr) 2000-09-21 2001-09-19 Derives d'acide phenylpropionique

Country Status (2)

Country Link
AU (1) AU2001288067A1 (fr)
WO (1) WO2002024633A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030193A1 (fr) * 2003-09-25 2005-04-07 Wyeth Derives d'acide 4-(phenyl-ethylideneaminoxy-propoxy)-phenyl-acetique et composes correspondants utilises comme inhibiteurs de pai-1 permettant de traiter une deficience du systeme fibrinolytique et la thrombose
EP1602642A1 (fr) * 2003-03-13 2005-12-07 Ono Pharmaceutical Co., Ltd. Composes derives d'imino ether et medicaments renfermant ces composes comme principe actif
US10023528B2 (en) 2011-04-13 2018-07-17 Bayer Pharma Aktiengesellschaft Branched 3-phenylpropionic acid derivatives and their use
US11344519B2 (en) 2018-07-24 2022-05-31 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008126A1 (fr) * 1995-08-28 1997-03-06 American Home Products Corporation Acides phenoxyacetiques en tant qu'inhibiteurs de l'aldose reductase et agents anti-hyperglycemiants
EP0916651A1 (fr) * 1996-04-04 1999-05-19 Sankyo Company, Limited Derives d'acide phenylalkylcarboxylique
JPH11193272A (ja) * 1997-10-01 1999-07-21 Sankyo Co Ltd フェニルアルキルカルボン酸誘導体を含有する医薬

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008126A1 (fr) * 1995-08-28 1997-03-06 American Home Products Corporation Acides phenoxyacetiques en tant qu'inhibiteurs de l'aldose reductase et agents anti-hyperglycemiants
EP0916651A1 (fr) * 1996-04-04 1999-05-19 Sankyo Company, Limited Derives d'acide phenylalkylcarboxylique
JPH11193272A (ja) * 1997-10-01 1999-07-21 Sankyo Co Ltd フェニルアルキルカルボン酸誘導体を含有する医薬

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1602642A1 (fr) * 2003-03-13 2005-12-07 Ono Pharmaceutical Co., Ltd. Composes derives d'imino ether et medicaments renfermant ces composes comme principe actif
EP1602642A4 (fr) * 2003-03-13 2006-11-08 Ono Pharmaceutical Co Composes derives d'imino ether et medicaments renfermant ces composes comme principe actif
WO2005030193A1 (fr) * 2003-09-25 2005-04-07 Wyeth Derives d'acide 4-(phenyl-ethylideneaminoxy-propoxy)-phenyl-acetique et composes correspondants utilises comme inhibiteurs de pai-1 permettant de traiter une deficience du systeme fibrinolytique et la thrombose
JP2007506773A (ja) * 2003-09-25 2007-03-22 ワイス 線溶系の障害および血栓症の治療用のｐａｉ−１阻害剤としての、４−（フェニル−エチリデンアミノキシ−プロポキシ）−フェニル−酢酸誘導体および関連化合物
US10023528B2 (en) 2011-04-13 2018-07-17 Bayer Pharma Aktiengesellschaft Branched 3-phenylpropionic acid derivatives and their use
US10259776B2 (en) 2011-04-13 2019-04-16 Bayer Intellectual Property Gmbh Branched 3-phenylpropionic acid derivatives and their use
US11377417B2 (en) 2011-04-13 2022-07-05 Bayer Intellectual Property Gmbh Branched 3-phenylpropionic acid derivatives and their use
US11344519B2 (en) 2018-07-24 2022-05-31 Bayer Pharma Aktiengesellschaft Orally administrable modified-release pharmaceutical dosage form

Also Published As

Publication number Publication date
AU2001288067A1 (en) 2002-04-02

Similar Documents

Publication Publication Date Title
WO1996016046A3 (fr) Nouvelles benzylpyrimidines
CA2317462A1 (fr) Composes de 4-(2-ceto-1-benzimidazolinyl)piperidine, utiles comme agonistes du recepteur orl1
WO2002101007A3 (fr) Composes benzamides anti-pathogenes
EP1813270A4 (fr) Inhibiteurs des proteines de la famille hsp90
WO2002044153A8 (fr) Derives de 4-aryle pyridine
WO1999000373A8 (fr) Derives de benzimidazole
AU2854399A (en) NF-kappa inhibitors containing as the active ingredient phenylmethyl benzoquinone
EP0640586A4 (fr) Derive de stilbene et derive d'analogue de stilbene, et utilisation de ces derives.
CA2226894A1 (fr) Derives de 2-(4-substitue)-benzylamino-2-methylpropanamide
EP1295879A4 (fr) Compositions medicinales contenant des derives de propenone
WO2002024633A1 (fr) Derives d'acide phenylpropionique
DE50101861D1 (de) Tocotrienolchinon- zyklisierungsprodukte mit antihypercholesterin wirkung
ES2093091T3 (es) Derivado de glutation.
EP1435353A4 (fr) Nouveau compose heterocyclique et agent anti-inflammatoire
HK1049335A1 (en) Hydrates and crystals of a neuraminic acid compound.
EP1437339A4 (fr) Derives d'acides benzoiques substitues possedant une activite d'inhibition de nf-kappa b
WO2001019811A3 (fr) Composes de n-arymethylthioanilide utiles pour inhiber la replication du vih
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
WO2004099130A3 (fr) Inhibiteur de cox
EP0773214A4 (fr) Acide du type trifluoromethylquinoleinecarboxylique
EP1481969A4 (fr) Composes derives de piperidine et medicaments contenant ces composes en tant que principe actif
EP1130018A4 (fr) Medicaments contre la dependance aux drogues
EP0947515A4 (fr) Nouveaux derives de naphthyridine
EP1219619A4 (fr) Derives de piperidine
AU1651201A (en) Amidinophenylpyruvic acid derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN CO CZ HU ID IL IN KR MX NO NZ PL RU SG SK US ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase